

Pharma-Bio Serv, Inc.  
Form 8-K  
April 30, 2012

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 or 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 24, 2012

Pharma-Bio Serv, Inc.  
(Exact Name of Registrant as Specified in Its Charter)

Delaware  
(State or Other Jurisdiction of Incorporation)

0-50956  
(Commission File Number)

20-0653570  
(I.R.S. Employer Identification No.)

6 Road 696, Dorado, Puerto Rico  
(Address of Principal Executive Offices)

00646  
(Zip Code)

(787) 278-2709  
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-



Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 24, 2012, Elizabeth Plaza, the President, Chief Executive Officer and Chair of the Board of Directors (the "Board") of Pharma-Bio Serv, Inc. (the "Company"), announced that she is stepping down as President and Chief Executive Officer of the Company, effective as of September 30, 2012, to spend more time with her family. Ms. Plaza will continue to serve as Chair of the Board.

The Board of Directors will begin its search for Ms. Plaza's replacement in the upcoming weeks.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMA-BIO SERV, INC.

Date: April 30, 2012

By: /s/ Pedro J. Lasanta  
Pedro J. Lasanta  
Chief Financial Officer